UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number  001-37526

Zynerba Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
(484) 581-7505
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, par value $0.001 per share
(Title of each class of securities covered by this Form)

None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 
Rule 12g-4(a)(1)
☒
 
Rule 12g-4(a)(2)
☐
 
Rule 12h-3(b)(1)(i)
☒
 
Rule 12h-3(b)(1)(ii)
☐
 
Rule 15d-6
☐
 
Rule 15d-22(b)
☐

Approximate number of holders of record as of the certification or notice date: one (1).

Pursuant to the requirements of the Securities Exchange Act of 1934, Zynerba Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.


Date:
October 19, 2023
  
ZYNERBA PHARMACEUTICALS, INC.
         
     
By:
/s/ Christian Ulrich
     
Name:
Christian Ulrich
     
Title:
Secretary


Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Zynerba Pharmaceuticals Charts.
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Zynerba Pharmaceuticals Charts.